Compare ESLT & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESLT | GMAB |
|---|---|---|
| Founded | 1966 | 1999 |
| Country | Israel | Denmark |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.8B | 21.1B |
| IPO Year | 1996 | N/A |
| Metric | ESLT | GMAB |
|---|---|---|
| Price | $699.39 | $33.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $550.33 | $40.40 |
| AVG Volume (30 Days) | 133.7K | ★ 1.5M |
| Earning Date | 11-18-2025 | 02-11-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | 68.63 | ★ 132.41 |
| EPS | 9.87 | ★ 25.10 |
| Revenue | ★ $7,720,284,000.00 | $3,845,670,022.00 |
| Revenue This Year | $18.47 | $24.85 |
| Revenue Next Year | $10.93 | $16.51 |
| P/E Ratio | $72.68 | ★ $1.35 |
| Revenue Growth | 18.35 | ★ 29.57 |
| 52 Week Low | $286.04 | $17.24 |
| 52 Week High | $719.99 | $34.30 |
| Indicator | ESLT | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 82.12 | 59.63 |
| Support Level | $574.29 | $30.35 |
| Resistance Level | $719.99 | $34.30 |
| Average True Range (ATR) | 14.38 | 0.68 |
| MACD | 10.90 | 0.12 |
| Stochastic Oscillator | 87.08 | 87.83 |
Elbit Systems Ltd is a technology company involved in producing a portfolio of systems and products for aircraft, land, and naval applications. The company's products are used for defense, homeland security, and commercial flight capabilities. Its systems and solutions may be installed on new platforms, or it may perform a comprehensive modernization program to transform a platform. Elbit Systems gives instructions to its customers on the proper maintenance of its products and will provide support team specialists when the customer cannot fix a problem. The company markets its systems and products as a prime contractor or as a subcontractor to government, defense, and homeland security contractors world wide.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.